Page 74 - Read Online

Zhang et al. Late recurrence of hepatocellular carcinoma

Dhillon AP, Patch D, Davidson BR, Sharma D, Rolles K, Burroughs D, Bartolozzi C, Lencioni R, Filipponi F. Efficacy and safety of
AK. Tumour size and differentiation in predicting recurrence of combination therapy with everolimus and sorafenib for recurrence of
hepatocellular carcinoma after liver transplantation: external validation hepatocellular carcinoma after liver transplantation. Transplant Proc
of a new prognostic score. Ann Surg Oncol 2008;15:3503-11. 2014;46:241-4.
31. Castroagudin JF, Molina-Pérez E, Ferreiro-Iglesias R, Abdulkader 38. Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M,
I, Otero-Antón E, Tomé S, Varo-Pérez E. Late recurrence of Garralda E, Testaillano M, Herrero I, Matilla A, Sangro B. Efficacy
hepatocellular carcinoma after liver transplantation: is an active and safety of sorafenib in combination with mammalian target of
surveillance for recurrence needed? Transplant Proc 2012;44:1565-7. rapamycin inhibitors for recurrent hepatocellular carcinoma after
32. Schreibman IR, Bejarano P, Martinez EJ, Regev A. Very late liver transplantation. Liver Transpl 2012;18:45-52.
recurrence of hepatocellular carcinoma after LT: case report and 39. Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W,
literature review. Transplant Proc 2006;38:3140-43. Lee SS, Park ES, Kaseb A, Kim BH, Kim WB, Yeon JE, Byun KS,
33. Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Chu IS, Kim SS, Wang XW, Thorgeirsson SS, Luk JM, Kang KJ,
Busuttil RW, Agopian VG. Predicting mortality in patients developing Heo J, Park YN, Lee JS. Genomic predictors for recurrence patterns
recurrent hepatocellular carcinoma after liver transplantation: impact of hepatocellular carcinoma: model derivation and validation. PLoS
of treatment modality and recurrence characteristics. Ann Surg 2016; Med 2014;11:e1001770.
DOI:10.1097/SLA.0000000000001894. 40. Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J,
34. Chok KSH. Management of recurrent hepatocellular carcinoma after Merion RM. Incidence and risk factors of hepatocellular carcinoma
liver transplant. World J Hepatol 2015;7:1142-8. recurrence after liver transplantation in the MELD era. Dig Dis Sci
35. Lee HY, Yang KH, Choi BH, Park YM, Yoon KT, Ryu JH, Chu CW. 2012;57:806-12.
Complete regression of recurrent advanced hepatocellular carcinoma 41. Wai CT, Woon WA, Tan YM, Lee KH, Tan KC. Younger age and
after liver transplantation in response to sorafenib treatment: a case presence of macrovascular invasion were independent significant
report. Transplant Proc 2016;48:247-50. factors associated with poor disease-free survival in hepatocellular
36. Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi carcinoma patients undergoing living donor liver transplantation.
G, Bhoori S, Mazzaferro V. Comparative efficacy of sorafenib versus Transplant Proc 2012;44:516-9.
best supportive care in recurrent hepatocellular carcinoma after liver 42. Iacob R, Iacob S, Gheorghe L, Gheorghe C, Hrehoret D, Brasoveanu
transplantation: a case-control study. J Hepatol 2013;59:59-66. V, Croitoru A, Herlea V, Popesu I. Outcome of liver transplantation
37. De Simone P, Crocetti L, Pezzati D, Bargellini I, Ghinolfi D, for hepatocellular carcinoma -- a single center experience. Chirurgia
Carrai P, Leonardi G, Della Pina C, Cioni D, Pollina L, Campani (Bucur) 2013;108:446-50.

66 Hepatoma Research ¦ Volume 3 ¦ April 10, 2017